Pancreatic Cancer Resectable Clinical Trials

11 recruiting

Pancreatic Cancer Resectable Trials at a Glance

11 actively recruiting trials for pancreatic cancer resectable are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Larissa, Chapel Hill, and Fukuoka. Lead sponsors running pancreatic cancer resectable studies include University of Thessaly, City of Hope Medical Center, and Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).

Browse pancreatic cancer resectable trials by phase

Treatments under study

About Pancreatic Cancer Resectable Clinical Trials

Looking for clinical trials for Pancreatic Cancer Resectable? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Cancer Resectable trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Cancer Resectable clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic NeoplasmsCancer of Pancreas+4 more
UNC Lineberger Comprehensive Cancer Center45 enrolled1 locationNCT03977233
Recruiting

Pancreatic Cancer Detection Consortium

Pancreatic CancerPancreatic CarcinomaPancreatic Ductal Adenocarcinoma+10 more
City of Hope Medical Center2,000 enrolled11 locationsNCT06388967
Recruiting
Early Phase 1

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Pancreatic Cancer ResectableChemotherapy-intolerant
Ruijin Hospital20 enrolled1 locationNCT06496373
Recruiting
Not Applicable

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

Gynecologic CancersBiliary Tract CancerCancer+6 more
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)48 enrolled1 locationNCT06731998
Recruiting

Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)

Pancreatic Cancer ResectablePancreatectomy
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)94 enrolled10 locationsNCT07157605
Recruiting
Phase 3

Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer

Pancreas CancerPancreas AdenocarcinomaPancreatic Cancer Resectable+3 more
Minia University262 enrolled1 locationNCT07081360
Recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Pancreatic Ductal AdenocarcinomaMinimal Residual DiseasectDNA+2 more
University Hospital, Montpellier37 enrolled1 locationNCT06287749
Recruiting
Not Applicable

Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure

Pancreatic Cancer ResectablePancreas Neoplasms
University of Thessaly76 enrolled1 locationNCT06914349
Recruiting

Effect of an Enhanced Recovery After Surgery Program on Outcomes After Pancreatoduodenectomy

Enhanced Recovery After SurgeryPancreatic Cancer ResectablePancreatectomy
University of Thessaly170 enrolled1 locationNCT06935448
Recruiting
Phase 2

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Pancreatic Cancer Resectable
Zhejiang Provincial People's Hospital57 enrolled1 locationNCT06722911
Recruiting
Phase 4

The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

Pancreatic Cancer Resectable
Xi'an Jiaotong University642 enrolled1 locationNCT06368063